跳至主要内容
临床试验/TCTR20200714001
TCTR20200714001尚未招募4 期

Comparing the effect of depo-medroxyprogesterone acetate (DMPA) and bromocriptine in women with symptomatic myoma uteri: a randomized controlled trial

none0 个研究点目标入组 126 人开始时间: 2020年7月14日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
126

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 Years 至 50 Years(—)
性别
Female

入选标准

  • 1.Woman ages between 20-50 years old.
  • 2.Myoma uteri confirmed by transvaginal ultrasound
  • 3.Pelvic pain or abnormal uterine bleeding
  • 4.Waiting for surgery or premenopausal woman
  • 5.Woman who can reading and writing

排除标准

  • 1.Heavy uterine bleeding that must have emergency treatment
  • 2.Transvaginal ultrasound found other disease in pelvic organ such as ovarian cancer
  • 3.Woman who take COC in 1 month or DMPA/implant in 3 months ago
  • 4.Deny to taked transvaginal ultrasound
  • 5.Pregnancy, lactation or fertility desires
  • 6.Abnormal liver or kidney function
  • 7.Ergot allergy
  • 8.Bleeding disorder
  • 9.Contraindication to bromocriptine including allergy, uncontrolled hypertension, pregnancy induced hypertension, myocardial infarction and severe psychological diseases.
  • 10.Contraindication to DMPA including uncontrolled hypertension, severe cirrhosis or liver tumor, Kidney or vascular complication from DM , venous thrombosis, cerebrovascular or myocardial infarction, breast cancer and undiagnosed abnormal uterine bleeding

研究者

发起方
none

相似试验